Compare AbbVie Inc (ABBV) vs iShares Core Growth Allocation ETF (AOR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares Core Growth Allocation ETF — how do they compare? AbbVie Inc trades at $252.1 (market cap $449.91B), while iShares Core Growth Allocation ETF trades at $68.55. The key difference: AbbVie Inc pays a 2.72% dividend while iShares Core Growth Allocation ETF pays none. Which is the better fit depends on your goals.
| ABBV | AOR | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $69.85 |
52-Week Low | $184.85 | $61.00 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.65, down 0.04% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $3.79. Recent positive Phase 2 data for ELAHERE in ovarian cancer and strong institutional buying activity highlight growth momentum. Valuation metrics appear elevated with a P/E of 124.83 and P/B of 245.29, though the company maintains a robust gross margin of 70.68% and consistent dividend payments.
The outlook remains positive with analyst consensus at 'Buy' and a $266.33 price target, representing 4.6% upside. Key opportunities include Skyrizi and Rinvoq growth offsetting Humira declines, while risks include high debt levels, patent cliffs in the 2030s, and elevated valuation multiples that could pressure returns if growth slows.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →
